The United States platelet rich plasma market size reached US$ 249.6 Million in 2023. Looking forward, the market is projected to reach US$ 546.2 Million by 2032, exhibiting a growth rate (CAGR) of 9.09% during 2023-2032.
Platelet-rich plasma (PRP) refers to a concentrated plasma protein that contains minor quantities of red blood cells. The platelets are suspended in a small amount of plasma after centrifugation and stimulate healing when injected into the body. PRP is widely administered by non-invasive therapies for long-lasting rejuvenation of ligaments and muscle fibers. Some of the common variants of PRP include pure platelet-rich plasma (P-PRP), leukocyte- and platelet-rich plasma (LPRP), leukocyte- and platelet-rich Fibrin (L-PRF), and pure platelet-rich fibrin (P-PRF).
The rising prevalence of chronic tendon injuries in vital organs is currently bolstering the demand for PRP-based therapies in the US. Furthermore, increasing adoption of effective therapies for treating muscle and acute ligament tearing, arthritis, fractures, orthopedic impairments, etc., is also propelling the market growth. In line with this, the growing awareness towards numerous benefits of PRP treatment in preventing inflammation, encouraging new cartilage formulation, and inducing natural lubrication fluid production, is further augmenting the product demand in the country.
Moreover, the rising deployment of advanced healthcare facilities for sports clubs and teams is also catalyzing the adoption of PRP-based therapies for treating common injuries in athletes, such as lumbar spine disc pain, rotator cuff injuries, shoulder pain and instability, tennis/golfer’s elbow, etc. Apart from this, the expanding cosmetic surgery sector in the United States is further driving the utilization of PRP-based procedures for improving facial shape and volume. In the coming years, the increasing healthcare expenditures along with the rising demand for non-invasive medical procedures will continue to spur the demand for PRP-based therapies in the United States.
2. What is the expected growth rate of the United States platelet rich plasma market during 2024-2032?
3. What are the key factors driving the United States platelet rich plasma market?
4. What has been the impact of COVID-19 on the United States platelet rich plasma market?
5. What is the breakup of the United States platelet rich plasma market based on the product type?
6. What is the breakup of the United States platelet rich plasma market based on the origin?
7. What is the breakup of the United States platelet rich plasma market based on the application?
8. What is the breakup of the United States platelet rich plasma market based on the end user?
9. What are the key regions in the United States platelet rich plasma market?
10. Who are the key players/companies in the United States platelet rich plasma market?
Platelet-rich plasma (PRP) refers to a concentrated plasma protein that contains minor quantities of red blood cells. The platelets are suspended in a small amount of plasma after centrifugation and stimulate healing when injected into the body. PRP is widely administered by non-invasive therapies for long-lasting rejuvenation of ligaments and muscle fibers. Some of the common variants of PRP include pure platelet-rich plasma (P-PRP), leukocyte- and platelet-rich plasma (LPRP), leukocyte- and platelet-rich Fibrin (L-PRF), and pure platelet-rich fibrin (P-PRF).
The rising prevalence of chronic tendon injuries in vital organs is currently bolstering the demand for PRP-based therapies in the US. Furthermore, increasing adoption of effective therapies for treating muscle and acute ligament tearing, arthritis, fractures, orthopedic impairments, etc., is also propelling the market growth. In line with this, the growing awareness towards numerous benefits of PRP treatment in preventing inflammation, encouraging new cartilage formulation, and inducing natural lubrication fluid production, is further augmenting the product demand in the country.
Moreover, the rising deployment of advanced healthcare facilities for sports clubs and teams is also catalyzing the adoption of PRP-based therapies for treating common injuries in athletes, such as lumbar spine disc pain, rotator cuff injuries, shoulder pain and instability, tennis/golfer’s elbow, etc. Apart from this, the expanding cosmetic surgery sector in the United States is further driving the utilization of PRP-based procedures for improving facial shape and volume. In the coming years, the increasing healthcare expenditures along with the rising demand for non-invasive medical procedures will continue to spur the demand for PRP-based therapies in the United States.
Key Market Segmentation
This report provides an analysis of the key trends in each sub-segment of the United States platelet rich plasma market report, along with forecasts at the country level from 2024-2032. The report has categorized the market based on product type, origin, application, and end user.Breakup by Product Type:
- Pure Platelet-Rich Plasma (P-PRP)
- Leukocyte- and Platelet-Rich Plasma (LPRP)
- Leukocyte- and Platelet-Rich Fibrin (L-PRF)
- Pure Platelet-Rich Fibrin (P-PRF)
Breakup by Origin:
- Autologous PRP
- Homologous PRP
- Allogeneic PRP
Breakup by Application:
- Orthopedics
- Cosmetic Surgery and Dermatology
- Neurosurgery
- General Surgery
- Cardiothoracic Surgery
- Urology
- Ophthalmology
- Others
Breakup by End User:
- Hospitals and Clinics
- Research Institutes
- Others
Breakup by Region:
- Northeast
- Midwest
- South
- West
Competitive Landscape
The competitive landscape of the industry has also been examined with some of the key players being Arteriocyte Medical Systems Inc. (Isto Technologies II LLC), Arthrex Inc., Depuy Synthes, Inc. (Johnson & Johnson), Dr Prp USA LLC, EmCyte Corporation, Exactech Inc., Glofinn America LLC (Glofinn Co. Ltd.), Regen Lab USA LLC, Stryker Corporation, Terumo BCT Inc. (Terumo Corporation), ThermoGenesis Holdings Inc. and Zimmer Biomet Holdings Inc.Key Questions Answered in This Report
1. What was the size of the United States platelet rich plasma market in 2023?2. What is the expected growth rate of the United States platelet rich plasma market during 2024-2032?
3. What are the key factors driving the United States platelet rich plasma market?
4. What has been the impact of COVID-19 on the United States platelet rich plasma market?
5. What is the breakup of the United States platelet rich plasma market based on the product type?
6. What is the breakup of the United States platelet rich plasma market based on the origin?
7. What is the breakup of the United States platelet rich plasma market based on the application?
8. What is the breakup of the United States platelet rich plasma market based on the end user?
9. What are the key regions in the United States platelet rich plasma market?
10. Who are the key players/companies in the United States platelet rich plasma market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 United States Platelet Rich Plasma Market
6 Market Breakup by Product Type
7 Market Breakup by Origin
8 Market Breakup by Application
9 Market Breakup by End User
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Arteriocyte Medical Systems Inc. (Isto Technologies II LLC)
- Arthrex Inc.
- Depuy Synthes Inc. (Johnson & Johnson)
- Dr Prp USA LLC
- EmCyte Corporation
- Exactech Inc.
- Glofinn America LLC (Glofinn Co. Ltd.)
- Regen Lab USA LLC
- Stryker Corporation
- Terumo BCT Inc. (Terumo Corporation)
- ThermoGenesis Holdings Inc.
- Zimmer Biomet Holdings Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 136 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 249.6 Billion |
| Forecasted Market Value ( USD | $ 546.2 Billion |
| Compound Annual Growth Rate | 9.0% |
| Regions Covered | United States |
| No. of Companies Mentioned | 12 |
